Loading...
•
Sep 30, 2022
Scorpius Holdings Q3 2022 Earnings Report
NightHawk Biosciences reported results for the third quarter of 2022, including revenue of $6 million driven by ANTHIM sales, and a net loss of $13 million.
Key Takeaways
NightHawk Biosciences reported $6 million in revenue for Q3 2022, primarily from the sale of ANTHIM to Canada's National Emergency Strategic Stockpile. The company's net loss was $13 million, or $0.51 per share. The company is deprioritizing its oncology programs to focus on biomanufacturing and medical countermeasures.
Revenue for Q3 2022 was $6 million, driven by product sales of ANTHIM to the Canadian government.
Product cost of sales for Q3 2022 was $6.4 million, related to the ANTHIM sale.
Research and development expenses increased to $6.9 million for Q3 2022.
Net loss attributable to NightHawk Biosciences was $13.0 million, or ($0.51) per basic and diluted share for Q3 2022.
Scorpius Holdings
Scorpius Holdings
Forward Guidance
The company is focused on advancing its biodefense and biomanufacturing efforts, including investments in its Scorpion San Antonio biologics manufacturing facility and a planned facility in Manhattan, Kansas. The company is deprioritizing oncology programs.